Coivas review
One monthly number is published. Almost nothing surrounding it is.
The verdict
Coivas publishes $149 a month for compounded semaglutide. No dose, no coverage list and no statement about what the figure does as the dose rises.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- From
- From $149/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
Coivas sells compounded semaglutide by injection. One figure is published. The catalog beyond that line is thin.
Who writes the prescription, and what do they see?
A prescription precedes dispensing and the pages describe the offer rather than the person writing it. The intake is not documented, and neither is what a clinician reviews before approving a refill.
Remote and lightly described. The published material is a price and a product, which is a smaller disclosure than most compounded sellers make even at higher figures.
What happens when the dose goes up?
Nothing is published on dose at all — not a milligram figure, not a statement about the price at a higher one. A reader cannot tell whether $149 buys 0.25 milligrams or 2.4, which makes the figure hard to set beside any other.
What the price includes
$149 is competitive against the median here, and six months at it comes to $894. Both statements assume the dose does not move and that nothing is added at checkout, and Coivas publishes nothing that confirms either assumption.
What it claims, and what it cites
Compounded rather than manufactured. A pharmacy prepares it and the FDA does not review it before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: A monthly figure is published up front
- Strength: Published figure sits under $150
- Limitation: No milligram dose stated anywhere
- Limitation: No state coverage list recorded
- Limitation: Nothing published about dose pricing
- Limitation: One molecule, one format
What the evidence says about this kind of treatment
The assessment above is about Coivas. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A buyer comparing headline figures who will ask the rest before ordering.
- Wrong for
- A buyer who needs the dose behind a price before treating it as comparable.
The evidence behind what Coivas prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How Coivas compares
| Seller | Who it suits | Go |
|---|---|---|
 Bon Health | Readers who can pick a commitment length and want every rung priced before they choose | See Bon Health → |
 Bloom MD | Buyers who want each tirzepatide dose priced in advance, with liraglutide as an option | See Bloom MD → |
 Bioverse | Readers who want semaglutide cheaply and ignore the struck figure beside it | See Bioverse → |
More GLP-1 telehealth sellers reviews: Rese WellnessRevive LongevityRilaRisen LabsRobinhood TelehealthRoyal Medical Center
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- What dose does $149 buy?
- Coivas does not say. No milligram figure appears beside the price, which means the number cannot be compared against a seller that publishes one.
- Does the price rise with the dose?
- Nothing is published either way. That is silence rather than a rising price, and the two should not be read as the same thing.
- Which states are served?
- No coverage list is recorded. Ask before ordering.
- Is Coivas expensive compared with other GLP-1 telehealth sellers?
- Coivas publishes a starting figure of $149/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts Coivas below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.